GOVX
GOVX clinical trials: GeoVax Labs, Inc.
Every trial on ClinicalTrials.gov where GeoVax Labs, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 4
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
GOVX on the catalyst calendar · GOVX registry changes
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT04977024SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerGeoVax, Inc. · COVID-19 InfectionActive, not recruitingGOVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2025ActualPhase 1/Phase 2NCT04639466A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 InfectionGeoVax, Inc. · COVID-19 InfectionCompletedGOVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2023ActualPhase 1/Phase 2NCT03754933Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck CancerGeoVax, Inc. · Recurrent Head and Neck CancerCompletedGOVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2014ActualPhase 1NCT01378156A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ARTGeoVax, Inc. · HIV-1 InfectionCompletedGOVXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2024ActualPhase 1/Phase 2NCT04357821Combinatorial Therapy to Induce an HIV RemissionUniversity of California, San Francisco · HIV/AIDSCompletedGOVXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2022Sponsor estimatePhase 1NCT04041674Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120...National Institute of Allergy and Infectious Diseases (NIAID) · HIV InfectionsWithdrawnGOVXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1NCT01571960Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive AdultsNational Institute of Allergy and Infectious Diseases (NIAID) · HIV InfectionsCompletedGOVXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner